Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Gasperini

Showing results (31-40 of 203) with videos related to

Pageof 21
Sort By:
The Neurohospitalist|June 27, 2022
Dural Arteriovenous Fistula as a Reversible Cause of Progressive Parkinsonism and Dementia: A Case ReportLuca Prosperini, Mara Gentile, Monica Ricci, et al.
Cells|June 20, 2019
CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple SclerosisMartina Kunkl, Manolo Sambucci, Serena Ruggieri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2011
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosisLuca Prosperini, Costanza Giannì, Laura Leonardi, et al.
Frontiers in Neurology|August 1, 2022
Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of NeurologistsGirolama Alessandra Marfia, Diego Centonze, Marco Salvetti, et al.
Journal of Neurology|June 6, 2025
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspectiveChiara Zanetta, Claudio Gasperini, Maria Pia Amato, et al.
Journal of Neurology|February 21, 2021
Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapyRosa Cortese, Luca Prosperini, Alessandro Stasolla, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2010
Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosisNicola De Stefano, François Curtin, Bettina Stubinski, et al.
Frontiers in Neurology|December 17, 2020
Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple SclerosisAntonio Giorgio, Marco Battaglini, Giordano Gentile, et al.
Therapeutic Advances in Neurological Disorders|May 23, 2022
Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCERaymond Hupperts, Claudio Gasperini, Jan Lycke, et al.
Journal of Neurology|December 12, 2024
Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionalsClaudio Gasperini, Mario Alberto Battaglia, Federica Balzani, et al.
Pageof 21

Showing results (31-40 of 203) with videos related to

Sort By:
Pageof 21
The Neurohospitalist|June 27, 2022
Dural Arteriovenous Fistula as a Reversible Cause of Progressive Parkinsonism and Dementia: A Case ReportLuca Prosperini, Mara Gentile, Monica Ricci, et al.
Cells|June 20, 2019
CD28 Autonomous Signaling Up-Regulates C-Myc Expression and Promotes Glycolysis Enabling Inflammatory T Cell Responses in Multiple SclerosisMartina Kunkl, Manolo Sambucci, Serena Ruggieri, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2011
Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosisLuca Prosperini, Costanza Giannì, Laura Leonardi, et al.
Frontiers in Neurology|August 1, 2022
Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of NeurologistsGirolama Alessandra Marfia, Diego Centonze, Marco Salvetti, et al.
Journal of Neurology|June 6, 2025
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspectiveChiara Zanetta, Claudio Gasperini, Maria Pia Amato, et al.
Journal of Neurology|February 21, 2021
Clinical course of central nervous system demyelinating neurological adverse events associated with anti-TNF therapyRosa Cortese, Luca Prosperini, Alessandro Stasolla, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2010
Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosisNicola De Stefano, François Curtin, Bettina Stubinski, et al.
Frontiers in Neurology|December 17, 2020
Mapping the Progressive Treatment-Related Reduction of Active MRI Lesions in Multiple SclerosisAntonio Giorgio, Marco Battaglini, Giordano Gentile, et al.
Therapeutic Advances in Neurological Disorders|May 23, 2022
Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCERaymond Hupperts, Claudio Gasperini, Jan Lycke, et al.
Journal of Neurology|December 12, 2024
Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionalsClaudio Gasperini, Mario Alberto Battaglia, Federica Balzani, et al.
Pageof 21